Napo Pharmaceuticals Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: San Francisco CA United States (2001)
Status: Acquired by Jaguar Health (2017)

Organization Overview

First Clinical Trial
2001
NCT00312195
First Marketed Drug
2012
crofelemer (mytesi)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Napo Pharmaceuticals | Napo Pharmaceuticals, Inc. | NAPO PHARMS INC | Napp Pharmaceuticals Limited

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acquired Immunodeficiency Syndrome (Phase 4)

Back Pain (Phase 4)

Breast Neoplasms (Phase 2)

Diarrhea (Phase 4)

HIV Infections (Phase 4)

Immunologic Deficiency Syndromes (Phase 4)

Leukemia (Phase 3)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 3)

Leukemia, Lymphoid (Phase 3)

Low Back Pain (Phase 4)

Osteoarthritis (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 15